Artykuły w czasopismach na temat „Abstract Targeted radionuclide therapy (TRT)”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „Abstract Targeted radionuclide therapy (TRT)”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.
Nguyen, Thanh Phuong T., Caroline P. Kerr, Joseph J. Grudzinski, Carolina A. Ferreira, Julia Sheehan-Klenk, Ohyun Kwon, Maria Powers i in. "Abstract 6407: Radionuclide-specific effects of90Y-,177Lu-, or225Ac-NM600 targeted radionuclide therapy on tumor immunomodulation and enhanced immunotherapy response in syngeneic murine tumors". Cancer Research 83, nr 7_Supplement (4.04.2023): 6407. http://dx.doi.org/10.1158/1538-7445.am2023-6407.
Pełny tekst źródłaKerr, Caroline P., Joseph J. Grudzinski, Carolina A. Ferreira, David Adam, Julia Sheehan-Klenk, Amber M. Bates, Won Jong Jin i in. "Abstract 2828: Impact of sequencing of immune checkpoint blockade and targeted radionuclide therapy on murine tumor response". Cancer Research 83, nr 7_Supplement (4.04.2023): 2828. http://dx.doi.org/10.1158/1538-7445.am2023-2828.
Pełny tekst źródłaPal, Debjani, Miguel Toro Gonzáleza, Amber N. Bibleb, Brian Sanders, Anna Plechaty, Owee Kirpekar, Mircea Podar i Sandra M. Davern. "Abstract 480: Nanotherapeutic strategies to improve targeted radionuclide therapy". Cancer Research 84, nr 6_Supplement (22.03.2024): 480. http://dx.doi.org/10.1158/1538-7445.am2024-480.
Pełny tekst źródłaAdhikarla, Vikram, Dennis Awuah, Alexander B. Brummer, Enrico Caserta, Amrita Krishnan, Flavia Pichiorri, Megan M. Minnix i in. "Abstract 2732: A mathematical model for optimization of combination therapy involving targeted radionuclide and CAR-T cell therapy". Cancer Research 82, nr 12_Supplement (15.06.2022): 2732. http://dx.doi.org/10.1158/1538-7445.am2022-2732.
Pełny tekst źródłaKerr, Caroline P., Amber M. Bates, Joseph J. Grudzinski, Carolina A. Ferreira, Julia Sheehan-Klenk, David Adam, Maria Powers i in. "Abstract 1306: Radionuclide-specific effects of 90Y-, 177Lu-, or 225Ac-NM600 targeted radionuclide therapy on tumor immunomodulation and enhancing immunotherapy response in murine tumor models". Cancer Research 82, nr 12_Supplement (15.06.2022): 1306. http://dx.doi.org/10.1158/1538-7445.am2022-1306.
Pełny tekst źródłaAdhikarla, Vikram, Dennis Awuah, Enrico Caserta, Megan Minnix, Maxim Kuznetsov, Amrita Krishnan, Jeffrey Y. Wong i in. "Abstract 7374: Mathematical modeling of targeted radionuclide therapy and CAR-T cell immunotherapy for maximizing therapeutic efficacy in multiple myeloma". Cancer Research 84, nr 6_Supplement (22.03.2024): 7374. http://dx.doi.org/10.1158/1538-7445.am2024-7374.
Pełny tekst źródłaRuder, Samuel, Michael Sun, Andres Ricaurte Fajardo, Jones Nauseef, Zachary Davidson, Joseph Thomas, Sandra Huicochea Castellanos i in. "Abstract 7582: Descriptive analysis of patients with mCRPC and liver metastases receiving alpha and beta PSMA targeted radionuclide therapy (PSMA-TRT)". Cancer Research 84, nr 6_Supplement (22.03.2024): 7582. http://dx.doi.org/10.1158/1538-7445.am2024-7582.
Pełny tekst źródłaSheehan-Klenk, Julia, Caroline P. Kerr, Thanh P. Nguyen, Joseph J. Grudzinski, David Adam, Maria Powers, Raghava N. Sriramaneni i in. "Abstract 6117: Dose, dose rate, and linear energy transfer influence tumor immunologic and DNA damage response following alpha- and beta-emitting radionuclides". Cancer Research 83, nr 7_Supplement (4.04.2023): 6117. http://dx.doi.org/10.1158/1538-7445.am2023-6117.
Pełny tekst źródłaVorontsova, M., T. Karmakova, A. Pankratov i A. Kaprin. "Current Trends in Targeted Radionuclide Therapy Development". Medical Radiology and radiation safety 66, nr 6 (17.12.2021): 63–70. http://dx.doi.org/10.12737/1024-6177-2021-66-6-63-70.
Pełny tekst źródłavan der Wal, Bart C. H., i Ekaterina Dadachova. "Targeted Radionuclide Therapy of Cancer and Infections". International Journal of Molecular Sciences 24, nr 10 (22.05.2023): 9081. http://dx.doi.org/10.3390/ijms24109081.
Pełny tekst źródłaMetcalf, Julie, Alexander Nielsen, Suma Prabhu, Nicole Robinson, Sarah Marinacci, Natalie Grinshtein, Brigitte L. Theriault i in. "Abstract LB313: EGFRvIII-targeted alpha therapy shows significant therapeutic efficacy as both a single-agent and in combination with standard of care against preclinical GBM models". Cancer Research 83, nr 8_Supplement (14.04.2023): LB313. http://dx.doi.org/10.1158/1538-7445.am2023-lb313.
Pełny tekst źródłaKerr, Caroline P., Joseph J. Grudzinski, Thanh Phuong Nguyen, Reinier Hernandez, Jamey P. Weichert i Zachary S. Morris. "Developments in Combining Targeted Radionuclide Therapies and Immunotherapies for Cancer Treatment". Pharmaceutics 15, nr 1 (30.12.2022): 128. http://dx.doi.org/10.3390/pharmaceutics15010128.
Pełny tekst źródłaObata, Honoka, Mikako Ogawa i Michael R. Zalutsky. "DNA Repair Inhibitors: Potential Targets and Partners for Targeted Radionuclide Therapy". Pharmaceutics 15, nr 7 (11.07.2023): 1926. http://dx.doi.org/10.3390/pharmaceutics15071926.
Pełny tekst źródłaLi, Mengshi, Edwin A. Sagastume, Dongyoul Lee, Daniel McAlister, Anthony J. DeGraffenreid, Keith R. Olewine, Stephen Graves i in. "203/212Pb Theranostic Radiopharmaceuticals for Image-guided Radionuclide Therapy for Cancer". Current Medicinal Chemistry 27, nr 41 (8.12.2020): 7003–31. http://dx.doi.org/10.2174/0929867327999200727190423.
Pełny tekst źródłaAdhikarla, Vikram, Dennis Awuah, Alexander B. Brummer, Enrico Caserta, Amrita Krishnan, Flavia Pichiorri, Megan Minnix i in. "A Mathematical Modeling Approach for Targeted Radionuclide and Chimeric Antigen Receptor T Cell Combination Therapy". Cancers 13, nr 20 (15.10.2021): 5171. http://dx.doi.org/10.3390/cancers13205171.
Pełny tekst źródłaMalcolm, Javian, Nadia Falzone, Boon Lee i Katherine Vallis. "Targeted Radionuclide Therapy: New Advances for Improvement of Patient Management and Response". Cancers 11, nr 2 (25.02.2019): 268. http://dx.doi.org/10.3390/cancers11020268.
Pełny tekst źródłaRuigrok, Eline A. M., Wytske M. van Weerden, Julie Nonnekens i Marion de Jong. "The Future of PSMA-Targeted Radionuclide Therapy: An Overview of Recent Preclinical Research". Pharmaceutics 11, nr 11 (29.10.2019): 560. http://dx.doi.org/10.3390/pharmaceutics11110560.
Pełny tekst źródłaMüller, Cristina, Martin Béhé, Susanne Geistlich, Nicholas P. van der Meulen i Roger Schibli. "Targeted Radiotherapeutics from 'Bench-to-Bedside'". CHIMIA International Journal for Chemistry 74, nr 12 (23.12.2020): 939–45. http://dx.doi.org/10.2533/chimia.2020.939.
Pełny tekst źródłaPatel, Ravi B., Reinier Hernandez, Peter Carlson, Joseph Grudzinski, Amber M. Bates, Justin C. Jagodinsky, Amy Erbe i in. "Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade". Science Translational Medicine 13, nr 602 (14.07.2021): eabb3631. http://dx.doi.org/10.1126/scitranslmed.abb3631.
Pełny tekst źródłaSun, M., C. Thomas, J. Stangl-Kremser, A. Fajardo, J. Palmer, J. Thomas, S. Huicochea Castellanos i in. "1822P PSMA-alpha targeted radionuclide therapy (TRT) with or without prior PSMA-beta TRT". Annals of Oncology 34 (październik 2023): S987. http://dx.doi.org/10.1016/j.annonc.2023.09.2770.
Pełny tekst źródłaSpoormans, Kaat, Melissa Crabbé, Lara Struelens, Marijke De Saint-Hubert i Michel Koole. "A Review on Tumor Control Probability (TCP) and Preclinical Dosimetry in Targeted Radionuclide Therapy (TRT)". Pharmaceutics 14, nr 10 (22.09.2022): 2007. http://dx.doi.org/10.3390/pharmaceutics14102007.
Pełny tekst źródłaAprile, Carlo, Onelio Geatti, Letizia Canziani i Lorenzo Lodola. "Editorial for the Special Issue “Molecular Biology in Targeted Radionuclide Therapy Radiopharmaceutical Design”". Current Issues in Molecular Biology 46, nr 3 (13.03.2024): 2398–401. http://dx.doi.org/10.3390/cimb46030152.
Pełny tekst źródłaFuneh, Cyprine Neba, Jessica Bridoux, Thomas Ertveldt, Timo W. M. De Groof, Dora Mugoli Chigoho, Parinaz Asiabi, Peter Covens, Matthias D’Huyvetter i Nick Devoogdt. "Optimizing the Safety and Efficacy of Bio-Radiopharmaceuticals for Cancer Therapy". Pharmaceutics 15, nr 5 (30.04.2023): 1378. http://dx.doi.org/10.3390/pharmaceutics15051378.
Pełny tekst źródłaPotluri, Hemanth, Carolina Ferreira, Joseph Grudzinski, Christopher Massey, Reinier Hernandez, Jamey Weichert i Douglas McNeel. "594 Combination of antigen-specific vaccination and targeted radionuclide therapy improves anti-tumor efficacy in a murine prostate model". Journal for ImmunoTherapy of Cancer 9, Suppl 2 (listopad 2021): A624. http://dx.doi.org/10.1136/jitc-2021-sitc2021.594.
Pełny tekst źródłaDelpassand, Ebrahim S., Mohammad Jawed Hashmi, Julia Kazakin, Omer Nawaz, Gabriella Garufi, Joanne Schindler i Luke Nordquist. "Abstract CT224: Preliminary efficacy and safety results from the (TATCIST) trial: A PSMA-directed targeted alpha therapy with FPI-2265 (225Ac-PSMA-I&T) for the treatment of metastatic castration-resistant prostate cancer (mCRPC)". Cancer Research 84, nr 7_Supplement (5.04.2024): CT224. http://dx.doi.org/10.1158/1538-7445.am2024-ct224.
Pełny tekst źródłaRuigrok, Eline A. M., Nicole S. Verkaik, Erik de Blois, Corrina de Ridder, Debra Stuurman, Stefan J. Roobol, Dik C. Van Gent, Marion de Jong, Wytske M. Van Weerden i Julie Nonnekens. "Preclinical Assessment of the Combination of PSMA-Targeting Radionuclide Therapy with PARP Inhibitors for Prostate Cancer Treatment". International Journal of Molecular Sciences 23, nr 14 (21.07.2022): 8037. http://dx.doi.org/10.3390/ijms23148037.
Pełny tekst źródłaWilliams, L. "WE-E-214-03: Biology and Physiology of Targeted Radionuclide Therapy (TRT)". Medical Physics 38, nr 6Part33 (czerwiec 2011): 3822. http://dx.doi.org/10.1118/1.3613392.
Pełny tekst źródłaSpeer, T. W., P. Bernhardt, B. Bednarz, P. Harari, J. Saker i B. Thomadsen. "Feasibility of the Systemic Cure of Cancer With Targeted Radionuclide Therapy (TRT)". International Journal of Radiation Oncology*Biology*Physics 84, nr 3 (listopad 2012): S709. http://dx.doi.org/10.1016/j.ijrobp.2012.07.1898.
Pełny tekst źródłaPotluri, Hemanth K., Carolina A. Ferreira, Joseph Grudzinski, Christopher Massey, Eduardo Aluicio-Sarduy, Jonathan W. Engle, Ohyun Kwon i in. "Antitumor efficacy of 90Y-NM600 targeted radionuclide therapy and PD-1 blockade is limited by regulatory T cells in murine prostate tumors". Journal for ImmunoTherapy of Cancer 10, nr 8 (sierpień 2022): e005060. http://dx.doi.org/10.1136/jitc-2022-005060.
Pełny tekst źródłaAkil, Hussein, Mercedes Quintana, Jérémy H. Raymond, Tommy Billoux, Valentin Benboubker, Sophie Besse, Philippe Auzeloux i in. "Efficacy of Targeted Radionuclide Therapy Using [131I]ICF01012 in 3D Pigmented BRAF- and NRAS-Mutant Melanoma Models and In Vivo NRAS-Mutant Melanoma". Cancers 13, nr 6 (20.03.2021): 1421. http://dx.doi.org/10.3390/cancers13061421.
Pełny tekst źródłaMüller, Cristina, Maria De Prado Leal, Marco D. Dominietto, Christoph A. Umbricht, Sairos Safai, Rosalind L. Perrin, Martina Egloff i in. "Combination of Proton Therapy and Radionuclide Therapy in Mice: Preclinical Pilot Study at the Paul Scherrer Institute". Pharmaceutics 11, nr 9 (2.09.2019): 450. http://dx.doi.org/10.3390/pharmaceutics11090450.
Pełny tekst źródłaMdanda, Sipho, Lindokuhle M. Ngema, Amanda Mdlophane, Mike M. Sathekge i Jan Rijn Zeevaart. "Recent Innovations and Nano-Delivery of Actinium-225: A Narrative Review". Pharmaceutics 15, nr 6 (13.06.2023): 1719. http://dx.doi.org/10.3390/pharmaceutics15061719.
Pełny tekst źródłaSun, M., C. Thomas, F. Orlando, M. Sigouros, J. Osborne, J. Nauseef, A. M. Molina i in. "1390P Circulating tumor DNA (ctDNA) and prognosis with PSMA-targeted radionuclide therapy (TRT)". Annals of Oncology 33 (wrzesień 2022): S1179. http://dx.doi.org/10.1016/j.annonc.2022.07.1522.
Pełny tekst źródłade Roode, Kim E., Lieke Joosten i Martin Behe. "Towards the Magic Radioactive Bullet: Improving Targeted Radionuclide Therapy by Reducing the Renal Retention of Radioligands". Pharmaceuticals 17, nr 2 (16.02.2024): 256. http://dx.doi.org/10.3390/ph17020256.
Pełny tekst źródłaCortiana, Viviana, Jade Gambill, Harshal Chorya, Diksha Mahendru, Fabiha Amin, Chandler H. Park i Yan Leyfman. "PSMA-Targeted Therapy: Advancements in Detection and Treatment Modalities with Dr. Scott T. Tagawa". Cancers 16, nr 10 (11.05.2024): 1833. http://dx.doi.org/10.3390/cancers16101833.
Pełny tekst źródłaSun, Michael, Charlene Thomas, Benedict Ho, Muhammad Junaid Niaz, Ana M. Molina, Cora N. Sternberg, David M. Nanus, Neil Harrison Bander i Scott T. Tagawa. "Long-term adverse events (AE) in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving prostate-specific membrane antigen (PSMA)-based targeted radionuclide therapy (TRT)." Journal of Clinical Oncology 39, nr 15_suppl (20.05.2021): 5055. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.5055.
Pełny tekst źródłaThomas, Joseph Earl, Jones T. Nauseef, Michael Philip Sun, Amie Patel, Angela Tan, Mahelia Bissassar, Jyothi Manohar i in. "Increased utilization of prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (PSMA-TRT) in African American (AA) patients at an academic medical center." Journal of Clinical Oncology 41, nr 6_suppl (20.02.2023): 36. http://dx.doi.org/10.1200/jco.2023.41.6_suppl.36.
Pełny tekst źródłaSodji, Quaovi H., Matthew H. Forsberg, Dan Cappabianca, Caroline P. Kerr, Lauren Sarko, Amanda Shea, David P. Adam i in. "Comparative Study of the Effect of Radiation Delivered by Lutetium-177 or Actinium-225 on Anti-GD2 Chimeric Antigen Receptor T Cell Viability and Functions". Cancers 16, nr 1 (30.12.2023): 191. http://dx.doi.org/10.3390/cancers16010191.
Pełny tekst źródłaLi, Mengshi, Dijie Liu, Dongyoul Lee, Yinwen Cheng, Nicholas J. Baumhover, Brenna M. Marks, Edwin A. Sagastume i in. "Targeted Alpha-Particle Radiotherapy and Immune Checkpoint Inhibitors Induces Cooperative Inhibition on Tumor Growth of Malignant Melanoma". Cancers 13, nr 15 (22.07.2021): 3676. http://dx.doi.org/10.3390/cancers13153676.
Pełny tekst źródłaEverix, Liesbeth, Shankari Nair, Cathryn H. S. Driver, Ingeborg Goethals, Mike M. Sathekge, Thomas Ebenhan, Charlot Vandevoorde i Julie Bolcaen. "Perspective on the Use of DNA Repair Inhibitors as a Tool for Imaging and Radionuclide Therapy of Glioblastoma". Cancers 14, nr 7 (3.04.2022): 1821. http://dx.doi.org/10.3390/cancers14071821.
Pełny tekst źródłaMagee, Kara, Ian R. Marsh, Michelle M. Turek, Joseph Grudzinski, Eduardo Aluicio-Sarduy, Jonathan W. Engle, Ilene D. Kurzman i in. "Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative (companion dog) setting". PLOS ONE 16, nr 8 (12.08.2021): e0255798. http://dx.doi.org/10.1371/journal.pone.0255798.
Pełny tekst źródłaMuralidhar, Anusha, Reinier Hernandez, Zachary S. Morris, Hansel Comas Rojas, Malick Bio Idrissou, Jamey P. Weichert i Douglas G. McNeel. "Myeloid-derived suppressor cells attenuate the antitumor efficacy of radiopharmaceutical therapy using90Y-NM600 in combination with androgen deprivation therapy in murine prostate tumors". Journal for ImmunoTherapy of Cancer 12, nr 4 (kwiecień 2024): e008760. http://dx.doi.org/10.1136/jitc-2023-008760.
Pełny tekst źródłaMétivier, Cassandra, Patricia Le Saëc, Joëlle Gaschet, Catherine Chauvet, Séverine Marionneau-Lambot, Peter O. Hofgaard, Bjarne Bogen i in. "Preclinical Evaluation of a 64Cu-Based Theranostic Approach in a Murine Model of Multiple Myeloma". Pharmaceutics 15, nr 7 (25.06.2023): 1817. http://dx.doi.org/10.3390/pharmaceutics15071817.
Pełny tekst źródłaVlachostergios, Panagiotis J., Muhammad Junaid Niaz, Seyed Ali Mosallaie, Paul J. Christos, Amy Hackett, Joseph R. Osborne, Yuliya Jhanwar i in. "Association of noninvasive, radiographic measurement of prostate-specific membrane antigen (PSMA) expression with response to PSMA-targeted radionuclide therapy (TRT)." Journal of Clinical Oncology 37, nr 15_suppl (20.05.2019): 5013. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.5013.
Pełny tekst źródłaReiner, Dora, Matthias Blaickner i Frank Rattay. "Discrete beta dose kernel matrices for nuclides applied in targeted radionuclide therapy (TRT) calculated withMCNP5". Medical Physics 36, nr 11 (2.10.2009): 4890–96. http://dx.doi.org/10.1118/1.3231995.
Pełny tekst źródłaSun, Michael, Justin M. Lebenthal, Jones T. Nauseef, Muhammad Junaid Niaz, Sabrina Guervil, Escarleth Fernandez, Amie Patel i in. "Baseline and post-treatment circulating tumor cell (CTC) counts with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) in men with metastatic castration-resistant prostate cancer (mCRPC)." Journal of Clinical Oncology 39, nr 6_suppl (20.02.2021): 158. http://dx.doi.org/10.1200/jco.2021.39.6_suppl.158.
Pełny tekst źródłaFernandes, Célia, Elisa Palma, Francisco Silva, Ana Belchior, Catarina I. G. Pinto, Joana F. Guerreiro, Hugo M. Botelho, Filipa Mendes, Paula Raposinho i António Paulo. "Searching for a Paradigm Shift in Auger-Electron Cancer Therapy with Tumor-Specific Radiopeptides Targeting the Mitochondria and/or the Cell Nucleus". International Journal of Molecular Sciences 23, nr 13 (29.06.2022): 7238. http://dx.doi.org/10.3390/ijms23137238.
Pełny tekst źródłaRao, Yi, Tara Viray, Kurt Gehlsen, Matt Harris, Lachlan McInnes, Olufolake Majekodunmi i Jason Lewis. "Abstract 6038: Copper-67 based targeted radiotherapy primes immunologically cold PDAC for immunotherapy". Cancer Research 84, nr 6_Supplement (22.03.2024): 6038. http://dx.doi.org/10.1158/1538-7445.am2024-6038.
Pełny tekst źródłaRuder, Samuel Francis, Michael Philip Sun, Charlene Thomas, Ana M. Molina, Jones T. Nauseef, Joseph Osborne, Cora N. Sternberg, David M. Nanus, Neil Harrison Bander i Scott T. Tagawa. "Comparison of adverse event rate of prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) with antibody or small molecule ligand targeting vector." Journal of Clinical Oncology 42, nr 4_suppl (1.02.2024): 161. http://dx.doi.org/10.1200/jco.2024.42.4_suppl.161.
Pełny tekst źródłaSanchez-Garcia, Manuel, Isabelle Gardin, Rachida Lebtahi i Arnaud Dieudonné. "A new approach for dose calculation in targeted radionuclide therapy (TRT) based on collapsed cone superposition: validation with90Y". Physics in Medicine and Biology 59, nr 17 (6.08.2014): 4769–84. http://dx.doi.org/10.1088/0031-9155/59/17/4769.
Pełny tekst źródła